<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03947255</url>
  </required_header>
  <id_info>
    <org_study_id>SGN35-028</org_study_id>
    <nct_id>NCT03947255</nct_id>
  </id_info>
  <brief_title>A Study of Retreatment With Brentuximab Vedotin in Subjects With Classic Hodgkin Lymphoma or CD30-expressing Peripheral T Cell Lymphoma</brief_title>
  <official_title>A Phase 2, Multicenter, Single-arm Study of Retreatment With Brentuximab Vedotin in Subjects With Relapsed or Refractory Classic Hodgkin Lymphoma (cHL) or CD30-expressing Peripheral T Cell Lymphoma (PTCL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seattle Genetics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seattle Genetics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look at whether brentuximab vedotin works and is safe in the re-treatment
      setting. To be in this study, patients must have already received brentuximab vedotin as
      treatment and have cancer that progressed (got worse) after stopping treatment.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study to determine the safety and efficacy of brentuximab vedotin in subjects with
      classic Hodgkin lymphoma (cHL) and systemic anaplastic large cell lymphoma (sALCL) or other
      CD30-expressing peripheral T cell lymphoma (PTCL) who experienced complete response (CR) or
      partial response (PR) with a brentuximab vedotin-containing regimen and subsequently
      experienced disease progression or relapse.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR) per BICR according to modified Lugano response criteria (Cheson 2014)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of participants with laboratory abnormalities</measure>
    <time_frame>Up to approximately 1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of response (DOR) per BICR according to modified Lugano response criteria (Cheson 2014)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free survival (PFS) per BICR according to modified Lugano response criteria (Cheson 2014)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete response (CR) per BICR according to modified Lugano response criteria</measure>
    <time_frame>Up to approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR per investigator assessment according to modified Lugano response criteria (Cheson 2014)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR per investigator assessment according to modified Lugano response criteria (Cheson 2014)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PFS per investigator assessment according to modified Lugano response criteria (Cheson 2014)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of CR per investigator assessment according to modified Lugano response criteria (Cheson 2014)</measure>
    <time_frame>Up to approximately 5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ORR per BICR according to Lugano response criteria (Cheson 2014)</measure>
    <time_frame>Up to approximately 1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Hodgkin Lymphoma</condition>
  <condition>Peripheral T Cell Lymphoma</condition>
  <condition>Anaplastic Large Cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>Brentuximab vedotin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>brentuximab vedotin</intervention_name>
    <description>1.8 mg/kg given intravenously (IV)</description>
    <arm_group_label>Brentuximab vedotin</arm_group_label>
    <other_name>ADCETRIS</other_name>
    <other_name>SGN-35</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed cHL, sALCL, or other CD30-expressing PTCL

          -  Previously treated with brentuximab vedotin containing regimen, with evidence of
             objective response, and subsequent disease progression or relapse after discontinuing
             treatment

          -  Documentation of disease relapse or progression â‰¥6 months after the last dose of
             brentuximab vedotin

          -  Fluorodeoxyglucose positron emission tomography- (FDG-PET) avid and bidimensional
             measurable disease of at least 1.5 cm in longest axis as documented by radiographic
             technique

          -  Eastern Cooperative Oncology Group (ECOG) performance status of less than or equal to
             2

          -  Must not be pregnant and, if of childbearing or fathering potential, must agree to use
             2 effective contraception methods during study and for 6 months following last dose of
             study drug

        Exclusion Criteria:

          -  Previously discontinued brentuximab vedotin due to any Grade 3 or higher toxicity

          -  Existing Grade 2 or higher peripheral neuropathy

          -  Previously refractory to treatment with brentuximab vedotin

          -  History of a cerebral vascular event, unstable angina, or myocardial infarction within
             6 months prior to first dose

          -  History of another malignancy within 3 years before first dose of study drug or any
             evidence of residual disease from previously diagnosed malignancy

          -  Acute or chronic graft-versus-host-disease (GvHD) or receiving immunosuppressive
             therapy as treatment for or prophylaxis agent against GvHD

          -  Active cerebral/meningeal disease

          -  History of progressive multifocal leukoencephalopathy (PML)

          -  Active uncontrolled Grade 3 (per NCI CTCAE v5.0) or higher viral, bacterial, or fungal
             infection within 2 weeks prior to first dose of study drug

          -  Chemotherapy, radiotherapy, biologics, and/or other antitumor treatment with
             immunotherapy that is not completed 4 weeks prior to first dose of study drug, unless
             underlying disease has progressed on treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie Lisano, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Seattle Genetics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Seattle Genetics Trial Information Support</last_name>
    <phone>866-333-7436</phone>
    <email>clinicaltrials@seagen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Brown</last_name>
      <phone>714-999-1465</phone>
      <email>elizabethg@pacificcancer.com</email>
    </contact>
    <investigator>
      <last_name>Veena Charu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Cancer Institute</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33028</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Procaccini</last_name>
      <phone>954-265-4325</phone>
      <email>NProcaccini@mhs.net</email>
    </contact>
    <investigator>
      <last_name>Jose Sandoval-Sus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Heather Woolridge</last_name>
      <phone>502-899-3366</phone>
      <email>Heather.woolridge@nortonhealthcare.org</email>
    </contact>
    <investigator>
      <last_name>Don Stevens, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tulane University Hospital and Clinic</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70112</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gaynelle Davis</last_name>
      <phone>504-988-6770</phone>
      <email>gdavis7@tulane.edu</email>
    </contact>
    <investigator>
      <last_name>Nakhle Saba, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute / Wayne State University</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carly Malburg</last_name>
      <phone>313-576-8204</phone>
      <email>malburgc@karmanos.org</email>
    </contact>
    <contact_backup>
      <last_name>Mary Domagalski</last_name>
      <phone>313-576-9767</phone>
      <email>domagalm@karmanos.org</email>
    </contact_backup>
    <investigator>
      <last_name>Erlene Seymour, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Comprehensive Cancer Centers of Nevada</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89169</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Meng-Yun (Megan) Wu</last_name>
      <phone>702-952-3400</phone>
      <email>megan.wu@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Edwin Kingsley, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Summit Medical Group</name>
      <address>
        <city>Florham Park</city>
        <state>New Jersey</state>
        <zip>07932</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michelle Mackenzie</last_name>
      <phone>973-436-1755</phone>
      <email>mmackenzie@smgnj.com</email>
    </contact>
    <investigator>
      <last_name>Benjamin Freeman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina/Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charlotte Gable</last_name>
      <phone>843-792-4271</phone>
      <email>gablech@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Irl Brian Greenwell, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Charles A. Sammons Cancer Center / Baylor University Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheila Powell</last_name>
      <phone>214-820-4015</phone>
      <email>Sheila.Powell@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Micah Burch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - Fort Worth 12th Avenue</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Beverly Gordon</last_name>
      <phone>817-413-1760</phone>
      <email>beverly.gordon@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Harris Naina, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders: Fortworth</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandi Halstead</last_name>
      <phone>817-759-7013</phone>
      <email>bhalstead@txcc.com</email>
    </contact>
    <investigator>
      <last_name>Ray Page, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center / University of Texas</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4095</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Karen Peyton</last_name>
      <phone>713-745-4367</phone>
      <email>KFPeyton@mdanderson.org</email>
    </contact>
    <contact_backup>
      <last_name>Mariana Gallardo</last_name>
      <phone>713-745-4367</phone>
      <email>MGallardo2@mdanderson.org</email>
    </contact_backup>
    <investigator>
      <last_name>Sairah Ahmed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology - San Antonio Medical Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78240</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lorinda (Lori) Molbe</last_name>
      <phone>210-424-2609</phone>
      <email>Lori.Molbe@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Roger Lyons, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 6, 2020</verification_date>
  <study_first_submitted>May 9, 2019</study_first_submitted>
  <study_first_submitted_qc>May 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 13, 2019</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CD30-expression</keyword>
  <keyword>sALCL</keyword>
  <keyword>PTCL</keyword>
  <keyword>cHL</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Hodgkin Disease</mesh_term>
    <mesh_term>Lymphoma, T-Cell</mesh_term>
    <mesh_term>Lymphoma, Large-Cell, Anaplastic</mesh_term>
    <mesh_term>Lymphoma, T-Cell, Peripheral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

